Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 4, 2009, Pages 1264-1273

  Johannsen, Trine Holm ^a   Kamstrup, Pia R ^a   Andersen, Rolf V ^a   Jensen, Gorm B ^b   Sillesen, Henrik ^c   Tybjaerg Hansen, Anne ^b,d,e   Nordestgaard, Borge G ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 65249148632     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1342     Document Type: Article

References (29)

1. Brunzell J, Deeb S 2001 Familial lipoprotein lipase deficiency, apo C-II deficiency, and hepatic lipase deficiency. In: Schriver CR, Beaudet AL, Valle D, Sly WS, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2789-2816
2. ThurenT2000 Hepatic lipase and HDL metabolism. Curr Opin Lipidol 11:277-283
3. Jansen H, Verhoeven AJM, Sijbrands EJG 2002 Hepatic lipase: a pro- or anti-atherogenic protein? J Lipid Res 43:1352-1362
4. Andersen RV, Wittrup HH, Tybjasrg-Hansen A, Steffensen R, Schnohr P, Nordestgaard BG 2003 Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk ofischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol 41:1972-1982
5. Isaacs A, Sayed-Tabatabaei FA, Njajou OT, Witteman JCM, van Duijn CM 2004 The -514 C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. J Clin Endocrinol Metab 89:3858-3863
6. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, TybjasrgHansen A 2000 Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 101:1907-1912
7. Hegele RA, Tu L, Connelly PW 1992 Human hepatic lipase mutations and polymorphisms. Hum Mutat 1:320 -324
8. Hegele RA, Little JA, Vezina C, Maguire GF, Tu L, Wolever TS, Jenkins DJA, Connelly PW 1993 Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb 13:720 -728
9. Knudsen P, Antikainen M, Ehnholm S, Uusi-Oukari M, Tenkanen H, Lahdenpera S, Kahri J, Tilly-Kiesi M, Bensadoun A, Taskinen M-R, Ehnholm C 1996 A compound heterozygote for hepatic lipase gene mutations Leu334->Phe and Thr383->Met: correlation between hepatic lipase activity and phenotypic expression. J Lipid Res 37:825-834
10. Knudsen P, Antikainen M, Uusi-Oukari M, Ehnholm S, LahdenperaS, BensadounA, FunkeH, WiebuschH, AssmannG, TaskinenM-R, Ehnholm C 1997 Heterozygous hepatic lipase deficiency, due to two missense mutations R186H and L334F, in the HL gene. Atherosclerosis 128:165-174
11. Smith GD, Ebrahim S 2004 Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 33:30 -42
12. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG 2002 Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 23:620 -626
13. Nordestgaard BG, Benn M, Schnohr P, Tybjasrg-Hansen A 2007 Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299 -308
14. Sethi AA,Tybjasrg-Hansen A, Andersen RV, NordestgaardBG 2004 Nanogen microelectronic chip for large-scale genotyping. Clin Chem 50:443-446
15. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R 1999 Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150:341-353
16. Guerra R, Wang J, Grundy SM, Cohen JC 1997 A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci USA 94:4532-4537
17. Durstenfeld A, Ben-Zeev O, Reue K, Stahnke G, Doolittle MH 1994Molecular characterization ofhuman hepatic lipase deficiency. In vitro expression oftwo naturally occurring mutations. Arterioscler Thromb 14:381-385
18. Cohen JC, Wang Z, Grundy SM, Stoesz MR, GuerraR 1994 Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest 94:2377-2384
19. 2 in man. Atherosclerosis 36:589 -593
20. Lambert G, Chase MB, Dugi K, Bensadoun A, Brewer Jr HB, Santamarina-Fojo S 1999 Hepatic lipase promotes the selective uptake of high-density lipoproteincholesteryl esters via the scavenger receptor B1. JLipid Res 40:1294-1303
21. Jacobs Jr DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA 1990 High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 131:32-47
22. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL 2006 Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37:1583-1633
23. Hokanson JE, Austin MA 1996 Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213-219
24. Hokanson JE, Cheng S, Snell-Bergeon JK, Fijal BA, Grow MA, Hung C, Erlich HA, Ehrlich J, Eckel RH, Rewers M 2002 A common promoter polymorphism in the hepatic lipase gene (LIPC-480C>T) is associated with an increase in coronary calcification in type 1 diabetes. Diabetes 51:1208-1213
25. Borggreve SE, Hillege HL, Wolffenbuttel BHR, de Jong PE, Zuurman MW, van der Steege G, van Tol A, Dullaart RPF; PREVEND Study Group 2006 An increased coronary risk is paradoxically associated with common cholesteryl ester transferproteingenevariationsthatrelateto higher high- densitylipoproteincholesterol: a population-based study. J Clin Endocrinol Metab 91:3382-3388
26. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR 1996 Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97:2917-2923
27. Kathiresan S, Melander O, Anevski D, Guiducci C,Burtt NP, Roos C,Hirschhorn JN, Berglund G, Hedblad B, Groop L, Altshuler DM, Newton-Cheh C, OrhoMelander M 2008 Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358:1240-1249
28. Frikke-Schmidt R, Nordestgaard BG, Stene MCA, Sethi AA, Remaley AT, Schnohr P, Grande P, Tybjasrg-Hansen A 2008 Association of loss-of-functions in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299:2524-2532
29. Nordestgaard BG, Wootton R, Lewis B 1995 Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 15:534-542